Katharina Kuenzel studied Life Science Engineering at the Friedrich-Alexander-University Erlangen-Nuremberg in Germany and finished her PhD in 2018 at the Institute of Medical Biotechnology. During her PhD, she investigated the potential of a human embryonal teratocarcinoma cell line for the use in a fluorescence-based testing method for the identification of neurotoxic substances. She is actually working as a PostDoc in the Potency Assay Skill Center at Boehringer Ingelheim Pharma GmbH & Co.KG. and is responsible for the implementation of robotic systems in order to automate potency assays.